Cargando…

Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors

BACKGROUND: The immunohistochemical demonstration of Enhancer of zeste homologue 2 (EZH2) proved to be a useful marker in several tumor types. It has been described to distinguish reliably hepatocellular carcinomas from liver adenomas and other benign hepatocellular lesions. However, no other types...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajósi-Kalcakosz, Szofia, Dezső, Katalin, Bugyik, Edina, Bödör, Csaba, Paku, Sándor, Pávai, Zoltán, Halász, Judit, Schlachter, Krisztina, Schaff, Zsuzsa, Nagy, Péter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3436720/
https://www.ncbi.nlm.nih.gov/pubmed/22809481
http://dx.doi.org/10.1186/1746-1596-7-86
_version_ 1782242679559553024
author Hajósi-Kalcakosz, Szofia
Dezső, Katalin
Bugyik, Edina
Bödör, Csaba
Paku, Sándor
Pávai, Zoltán
Halász, Judit
Schlachter, Krisztina
Schaff, Zsuzsa
Nagy, Péter
author_facet Hajósi-Kalcakosz, Szofia
Dezső, Katalin
Bugyik, Edina
Bödör, Csaba
Paku, Sándor
Pávai, Zoltán
Halász, Judit
Schlachter, Krisztina
Schaff, Zsuzsa
Nagy, Péter
author_sort Hajósi-Kalcakosz, Szofia
collection PubMed
description BACKGROUND: The immunohistochemical demonstration of Enhancer of zeste homologue 2 (EZH2) proved to be a useful marker in several tumor types. It has been described to distinguish reliably hepatocellular carcinomas from liver adenomas and other benign hepatocellular lesions. However, no other types of malignant liver tumors were studied so far. METHODS: To evaluate the diagnostic value of this protein in hepatic tumors we have investigated the presence of EZH2 by immunohistochemistry in hepatocellular carcinomas and other common hepatic tumors. EZH2 expression was examined in 44 hepatocellular carcinomas, 23 cholangiocarcinomas, 31 hepatoblastomas, 16 other childhood tumor types (rhabdomyosarcoma, neuroblastoma, Wilms’ tumor and rhabdoid tumor), 17 metastatic liver tumors 24 hepatocellular adenomas, 15 high grade dysplastic nodules, 3 biliary cystadenomas, 3 biliary hamartomas and 3 Caroli’s diseases. RESULTS: Most of the malignant liver tumors were positive for EZH2, but neither of the adenomas, cirrhotic/dysplastic nodules, reactive and hamartomatous biliary ductules stained positively. CONCLUSIONS: Our immunostainings confirm that EZH2 is a sensitive marker of hepatocellular carcinoma, but its specificity is very low, since almost all the investigated malignant liver tumors were positive regardless of their histogenesis. Based on these results EZH2 is a sensitive marker of malignancy in hepatic tumors. In routine surgical pathology EZH2 could be most helpful to diagnose cholangiocarcinomas, because as far as we know this is the first marker to distinguish transformed and reactive biliary structures. Although hepatoblastomas also express EZH2, the diagnostic significance of this observation seems to be quite limited whereas, the structurally similar, other blastic childhood tumors are also positive. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1173195902735693
format Online
Article
Text
id pubmed-3436720
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34367202012-09-08 Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors Hajósi-Kalcakosz, Szofia Dezső, Katalin Bugyik, Edina Bödör, Csaba Paku, Sándor Pávai, Zoltán Halász, Judit Schlachter, Krisztina Schaff, Zsuzsa Nagy, Péter Diagn Pathol Research BACKGROUND: The immunohistochemical demonstration of Enhancer of zeste homologue 2 (EZH2) proved to be a useful marker in several tumor types. It has been described to distinguish reliably hepatocellular carcinomas from liver adenomas and other benign hepatocellular lesions. However, no other types of malignant liver tumors were studied so far. METHODS: To evaluate the diagnostic value of this protein in hepatic tumors we have investigated the presence of EZH2 by immunohistochemistry in hepatocellular carcinomas and other common hepatic tumors. EZH2 expression was examined in 44 hepatocellular carcinomas, 23 cholangiocarcinomas, 31 hepatoblastomas, 16 other childhood tumor types (rhabdomyosarcoma, neuroblastoma, Wilms’ tumor and rhabdoid tumor), 17 metastatic liver tumors 24 hepatocellular adenomas, 15 high grade dysplastic nodules, 3 biliary cystadenomas, 3 biliary hamartomas and 3 Caroli’s diseases. RESULTS: Most of the malignant liver tumors were positive for EZH2, but neither of the adenomas, cirrhotic/dysplastic nodules, reactive and hamartomatous biliary ductules stained positively. CONCLUSIONS: Our immunostainings confirm that EZH2 is a sensitive marker of hepatocellular carcinoma, but its specificity is very low, since almost all the investigated malignant liver tumors were positive regardless of their histogenesis. Based on these results EZH2 is a sensitive marker of malignancy in hepatic tumors. In routine surgical pathology EZH2 could be most helpful to diagnose cholangiocarcinomas, because as far as we know this is the first marker to distinguish transformed and reactive biliary structures. Although hepatoblastomas also express EZH2, the diagnostic significance of this observation seems to be quite limited whereas, the structurally similar, other blastic childhood tumors are also positive. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1173195902735693 BioMed Central 2012-07-18 /pmc/articles/PMC3436720/ /pubmed/22809481 http://dx.doi.org/10.1186/1746-1596-7-86 Text en Copyright ©2012 Hajósi-Kalcakosz et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hajósi-Kalcakosz, Szofia
Dezső, Katalin
Bugyik, Edina
Bödör, Csaba
Paku, Sándor
Pávai, Zoltán
Halász, Judit
Schlachter, Krisztina
Schaff, Zsuzsa
Nagy, Péter
Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
title Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
title_full Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
title_fullStr Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
title_full_unstemmed Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
title_short Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
title_sort enhancer of zeste homologue 2 (ezh2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3436720/
https://www.ncbi.nlm.nih.gov/pubmed/22809481
http://dx.doi.org/10.1186/1746-1596-7-86
work_keys_str_mv AT hajosikalcakoszszofia enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT dezsokatalin enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT bugyikedina enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT bodorcsaba enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT pakusandor enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT pavaizoltan enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT halaszjudit enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT schlachterkrisztina enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT schaffzsuzsa enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors
AT nagypeter enhancerofzestehomologue2ezh2isareliableimmunohistochemicalmarkertodifferentiatemalignantandbenignhepatictumors